Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

Antitelomerase therapy provokes ALT and mitochondrial adaptive mechanisms in cancer.

Jian Hu | Soyoon Sarah Hwang | Marc Liesa | Boyi Gan | Ergun Sahin | Mariela Jaskelioff | Zhihu Ding | Haoqiang Ying | Adam T Boutin | Hailei Zhang | Shawn Johnson | Elena Ivanova | Maria Kost-Alimova | Alexei Protopopov | Yaoqi Alan Wang | Orian S Shirihai | Lynda Chin | Ronald A DePinho
Cell | 2012

To assess telomerase as a cancer therapeutic target and determine adaptive mechanisms to telomerase inhibition, we modeled telomerase reactivation and subsequent extinction in T cell lymphomas arising in Atm(-/-) mice engineered with an inducible telomerase reverse transcriptase allele. Telomerase reactivation in the setting of telomere dysfunction enabled full malignant progression with alleviation of telomere dysfunction-induced checkpoints. These cancers possessed copy number alterations targeting key loci in human T cell lymphomagenesis. Upon telomerase extinction, tumor growth eventually slowed with reinstatement of telomere dysfunction-induced checkpoints, yet growth subsequently resumed as tumors acquired alternative lengthening of telomeres (ALT) and aberrant transcriptional networks centering on mitochondrial biology and oxidative defense. ALT+ tumors acquired amplification/overexpression of PGC-1β, a master regulator of mitochondrial biogenesis and function, and they showed marked sensitivity to PGC-1β or SOD2 knockdown. Genetic modeling of telomerase extinction reveals vulnerabilities that motivate coincidental inhibition of mitochondrial maintenance and oxidative defense mechanisms to enhance antitelomerase cancer therapy.

Pubmed ID: 22341440

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: NIDDK NIH HHS, United States
    Id: R01-DK56690
  • Agency: NIDDK NIH HHS, United States
    Id: R01 DK035914
  • Agency: NCI NIH HHS, United States
    Id: U01 CA141508-04
  • Agency: NCI NIH HHS, United States
    Id: R01 CA084628-20
  • Agency: NCI NIH HHS, United States
    Id: R01 CA084628
  • Agency: NCI NIH HHS, United States
    Id: R01CA84628
  • Agency: NIDDK NIH HHS, United States
    Id: R01-DK074778
  • Agency: NIDDK NIH HHS, United States
    Id: R01 DK074778
  • Agency: NCI NIH HHS, United States
    Id: U01 CA141508
  • Agency: NCI NIH HHS, United States
    Id: U01CA141508

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Gene Expression Omnibus (GEO) (tool)

RRID:SCR_007303

Functional genomics data repository supporting MIAME-compliant data submissions. Includes microarray-based experiments measuring the abundance of mRNA, genomic DNA, and protein molecules, as well as non-array-based technologies such as serial analysis of gene expression (SAGE) and mass spectrometry proteomic technology. Array- and sequence-based data are accepted. Collection of curated gene expression DataSets, as well as original Series and Platform records. The database can be searched using keywords, organism, DataSet type and authors. DataSet records contain additional resources including cluster tools and differential expression queries.

View all literature mentions

Agilent Technologies (tool)

RRID:SCR_013575

Company provides laboratories worldwide with analytical instruments and supplies, clinical and diagnostic testing services, consumables, applications and expertise in life sciences and applied chemical markets.

View all literature mentions